NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $365.94 -15.07 (-3.96%) (As of 08/29/2024 ET) Add Compare Share Share Today's Range$364.58▼$389.4450-Day Range$357.30▼$457.2952-Week Range$227.21▼$459.77Volume515,202 shsAverage Volume243,569 shsMarket Capitalization$11.34 billionP/E Ratio37.30Dividend YieldN/APrice Target$423.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside15.6% Upside$423.00 Price TargetShort InterestHealthy3.75% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.62Based on 14 Articles This WeekInsider TradingN/AProj. Earnings Growth11.15%From $11.66 to $12.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector44th out of 940 stocksCommercial Physical Research Industry3rd out of 13 stocks 3.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.75% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 18.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.0 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Medpace this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 11.15% in the coming year, from $11.66 to $12.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 37.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 37.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 119.89.Price to Earnings Growth RatioMedpace has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 14.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchRoosevelt. Nixon. Harris. What’s the link?New Government Strike Force Patrolling America The government's new Strike Force is patrolling America as we speak – and this time, they're going much further than telling you to wear a mask and stay inside. It has nothing to do with the leadup to November. This is already in motion... and it's escalating quickly.Get the full story and learn how this could impact your money right here, while there's still time. About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesAugust 29 at 12:40 PM | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 28 at 7:34 AM | benzinga.comInsider Decision: Robert O Kraft Exercises Options At Medpace Hldgs For $2.78MAugust 29, 2024 | Stansberry Research (Ad)Roosevelt. Nixon. Harris. What’s the link?New Government Strike Force Patrolling America The government's new Strike Force is patrolling America as we speak – and this time, they're going much further than telling you to wear a mask and stay inside. It has nothing to do with the leadup to November. This is already in motion... and it's escalating quickly.August 26 at 4:02 PM | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 25, 2024 | stockhouse.comAn Investigation For Securities Fraud Has Been Launched Into Medpace Holdings Inc And The Schall Law Firm Is Seeking Stockholders To ParticipateAugust 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 380.000 putAugust 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 460.000 callAugust 20, 2024 | seekingalpha.comMedpace: Continued Business Growth With Asymmetrical Payoff OpportunityAugust 29, 2024 | Stansberry Research (Ad)Roosevelt. Nixon. Harris. What’s the link?New Government Strike Force Patrolling America The government's new Strike Force is patrolling America as we speak – and this time, they're going much further than telling you to wear a mask and stay inside. It has nothing to do with the leadup to November. This is already in motion... and it's escalating quickly.August 17, 2024 | finance.yahoo.comMEDP Sep 2024 420.000 put (MEDP240920P00420000)August 15, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 15, 2024 | finance.yahoo.comSkanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billionAugust 15, 2024 | msn.comRoad closures Saturday for Black Family Reunion Parade, Medpace 5KAugust 13, 2024 | nz.finance.yahoo.comMEDP Aug 2024 560.000 callAugust 13, 2024 | msn.comThermo Fisher Scientific Stock Sees RS Rating Jump To 81August 12, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 8, 2024 | nz.finance.yahoo.comMedpace Holdings Inc (01P.SG)August 5, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2024Today8/29/2024Next Earnings (Estimated)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Target$423.00 High Stock Price Target$452.00 Low Stock Price Target$336.00 Potential Upside/Downside+10.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio38.99 Forward P/E Ratio32.80 P/E Growth2Net Income$282.81 million Net Margins16.74% Pretax Margin19.57% Return on Equity55.14% Return on Assets19.82% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$2.03 billion Price / Sales5.84 Cash Flow$10.01 per share Price / Cash Flow38.23 Book Value$24.63 per share Price / Book15.53Miscellaneous Outstanding Shares30,983,000Free Float24,693,000Market Cap$11.85 billion OptionableOptionable Beta1.36 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.65MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $945.08kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $690.48kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1.12MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $914.64kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELSyneos HealthNASDAQ:SYNHLaboratory Co. of AmericaNYSE:LHNational ResearchNASDAQ:NRCView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 143,481 shares on 8/27/2024Ownership: 1.304%Cetera Investment AdvisersBought 263 shares on 8/22/2024Ownership: 0.038%Truist Financial CorpBought 648 shares on 8/21/2024Ownership: 0.012%Chase Investment Counsel CorpBought 231 shares on 8/19/2024Ownership: 0.029%Creative PlanningSold 59 shares on 8/16/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $306.53 at the beginning of 2024. Since then, MEDP stock has increased by 19.4% and is now trading at $365.94. View the best growth stocks for 2024 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Monday, July, 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.54 by $0.21. The firm's revenue was up 14.6% compared to the same quarter last year. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Medpace IPO? Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's top institutional investors include Riverbridge Partners LLC (1.73%), TD Asset Management Inc (1.65%), Renaissance Technologies LLC (1.43%) and Epoch Investment Partners Inc. (1.31%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD) and Bilibili (BILI). This page (NASDAQ:MEDP) was last updated on 8/29/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredPresident Kamala’s first act?The Fix Is In for 2024 If you've watched everything unfold over the past few weeks and wondered, "What in t...Stansberry Research | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off ou...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
